ClinicalTrials.gg

Program

org-34517

Also written as “PT150” and “SCH 900636”.

Its studies are mostly in Alcoholism · Depressive Disorder, led by 2 companies.

Furthest: phase 2, since May 10, 20184 company-led studies, 1 open or runningNext primary completion: Jul 31, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pop Test Oncology31 open or runningphase 1since May 10, 2018May 10, 2018Jul 31, 2028phase 1 · NCT06712602
Merck10 open or runningphase 2since Feb 11, 2009Feb 11, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 11, 2009First study: phase 2 study in Depressive DisorderNew to MerckMerck · NCT00844922 · 16 enrolled
  2. May 10, 2018Pop Test Oncology's first study: phase 1 study in AlcoholismNew to Pop Test OncologyPop Test Oncology · NCT03548714 · 10 enrolled · United States
  3. Mar 31, 2020Phase 1 study in AlcoholismPop Test Oncology · NCT04331288 · 10 enrolled · United States
  4. Nov 26, 2024Phase 1 study in AlcoholismPop Test Oncology · NCT06712602 · 34 planned · United States

Ahead

  1. Jul 31, 2028Primary completion: phase 1 study in AlcoholismPop Test Oncology · NCT06712602

TargetBeta

NR3C1 →read by rule
“Glucocorticoid receptor antagonist”ChEMBL 37, by rule

Other programs on NR3C1

ProgramCompanyFurthest phaseStudies
DexamethasoneruleAbbViephase 4174
BudesonideruleAstraZenecaphase 4167
fluticasone furoateruleGlaxoSmithKlinephase 497
PrednisoneruleJohnson & Johnsonphase 465
BeclomethasoneruleChiesi Farmaceuticiphase 446
PrednisoloneruleSanofiphase 434
betamethasone dipropionateruleLEO Pharmaphase 427
MethylprednisolonerulePfizerphase 423
dexamethasone phosphateruleeyegate-pharmaceuticals-incphase 421
vamorolonerulereveragen-biopharma-incphase 411
BetamethasoneruleLEO Pharmaphase 49
Triamcinoloneruleresearch-insight-llcphase 45

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT06712602Alcoholism · United States1RecruitingPop Test OncologyJul 31, 202834
NCT04331288Alcoholism · United States1CompletedPop Test OncologyOct 27, 202310
NCT03548714Alcoholism · United States1CompletedPop Test OncologyJul 15, 201910
NCT00844922Depressive Disorder2CompletedMerckJun 200616

How it is read

Names in the registry

  • “PT150”, 3 entries
  • “SCH 900636”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.